Microablative fractional CO2-laser therapy and the genitourinary syndrome of menopause: An observational study.

@article{Pitsouni2016MicroablativeFC,
  title={Microablative fractional CO2-laser therapy and the genitourinary syndrome of menopause: An observational study.},
  author={Eleni I Pitsouni and Themos Grigoriadis and Angeliki Tsiveleka and Dimitris Zacharakis and Stefano Salvatore and Stavros Athanasiou},
  journal={Maturitas},
  year={2016},
  volume={94},
  pages={
          131-136
        }
}
OBJECTIVES This study aimed to assess the effect of the Microablative Fractional CO2 Laser (CO2-laser) therapy on vaginal pathophysiology and the symptoms of the Genitourinary Syndrome of Menopause (GSM). METHODS Postmenopausal women with moderate to severe symptoms of GSM underwent three sessions of CO2-laser therapy at monthly intervals. Participants were evaluated at baseline and 4 weeks after the last treatment. MAIN OUTCOME MEASURES The primary outcomes were Vaginal Maturation Value… Expand

Paper Mentions

Interventional Clinical Trial
Vulvodynia is a debilitating chronic vulvar pain lasting at least 3 months without a clear identifiable cause that is challenging to treat effectively. Vulvodynia is a common pain… Expand
ConditionsVestibulodynia
InterventionDevice
Microablative fractional CO2 laser for the genitourinary syndrome of menopause: up to 12-month results
TLDR
Laser therapy may provide significant improvement and/or absence of GSM symptoms up to 12 months follow-up, irrespectively to the number of laser therapies applied, in short and long-term follow- up. Expand
CO2-laser for the genitourinary syndrome of menopause. How many laser sessions?
TLDR
Results of this study indicate that CO2-laser therapy may contribute to complete regression of dyspareunia and dryness and reestablishment of normal sexual function in postmenopausal women, in a dose-response manner. Expand
Microablative fractional CO2 laser for the genitourinary syndrome of menopause: power of 30 or 40 W?
TLDR
Comparing 30 versus 40 W power of CO2 laser for the therapy of genitourinary syndrome of menopause revealed that mean improvement or presence of all GSM symptoms and clinical signs was not statistically significant different. Expand
Pilot study of fractional CO2 laser therapy for genitourinary syndrome of menopause in gynecologic cancer survivors.
TLDR
Fractional CO2 laser therapy is feasible in gynecologic cancer survivors, with preliminary evidence of safety and improvement in sexual function compared with sham treatment, according to a pilot, multi-institutional randomized sham-controlled trial of women with Gynecologic cancers with dyspareunia and/or vaginal dryness. Expand
Safety and long-term efficacy of fractional CO2 laser treatment in women suffering from genitourinary syndrome of menopause.
TLDR
Fractional microablative CO2 laser treatment was associated with an improvement in symptoms of GSM and sexual function and scores on measures of sexual function, dyspareunia, and bothersomeness of sexual issues were improved from pre-treatment to long-term follow-up. Expand
CO2 laser and the genitourinary syndrome of menopause: a randomized sham-controlled trial
TLDR
CO2 laser could be proposed as an effective alternative treatment for the management of GSM as it is superior to sham treatments. Expand
Efficacy of fractional CO2 laser treatment in postmenopausal women with genitourinary syndrome: a multicenter study.
TLDR
The results show the effectiveness and a good degree of tolerance of treatment with the CO2 laser system in postmenopausal women with GSM. Expand
Fractional CO2 laser therapy for genitourinary syndrome of menopause for breast cancer survivors
TLDR
Fractional CO2 laser treatment for breast cancer survivors with dyspareunia and/or vaginal dryness is feasible and appears to reduce GSM symptoms across treatment and follow-up. Expand
Effectiveness of fractional CO2 laser in women with stress urinary incontinence
TLDR
The findings are in line with a previous study that showed the value of transvaginal CO2 fractional laser treatment for alleviation of SUI symptoms and its potential as an alternative treatment and improved sexual satisfaction in SUI patients. Expand
Patient-reported sexual function of breast cancer survivors with genitourinary syndrome of menopause after fractional CO2 laser therapy.
TLDR
In BC survivors with GSM, the total and individual domain scores of the FSFI and the FSDS-R improved after fractional CO2 laser therapy, indicating less sexually related distress. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 35 REFERENCES
A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study
TLDR
A 12-week treatment with the fractional CO2 laser was feasible and induced a significant improvement of VVA symptoms by ameliorating vaginal health in postmenopausal women. Expand
Vulvo-vaginal atrophy: a new treatment modality using thermo-ablative fractional CO2 laser.
TLDR
Thermo-ablative fractional CO2 laser could be a safe, effective and feasible option for the treatment of VVA symptoms in post-menopausal women. Expand
Fractional CO 2 laser for vulvovaginal atrophy ( VVA ) dyspareunia relief in breast cancer survivors
Purpose The aim of this study was to evaluate the efficacy of fractional CO2 laser therapy in breast cancer survivors as a therapeutic method for vulvovaginal atrophy (VVA) dyspareunia. Methods 50Expand
Sexual function after fractional microablative CO2 laser in women with vulvovaginal atrophy
TLDR
Fractional microablative CO 2 laser treatment is associated with a signifi cant improvement of sexual function and satisfaction with sexual life in postmenopausal women with VVA symptoms. Expand
Sexual function after fractional microablative CO2 laser in women with vulvovaginal atrophy
TLDR
Fractional microablative CO2 laser treatment is associated with a significant improvement of sexual function and satisfaction with sexual life in postmenopausal women with VVA symptoms. Expand
Fractional CO2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors
TLDR
The treatment with fractionated CO2 laser appeared to be a feasible and effective treatment for VVA dyspareunia in breast cancer survivors with contraindications to hormonal treatments. Expand
The effect of microablative fractional CO2 laser on vaginal flora of postmenopausal women
TLDR
MFCO2-Laser therapy is a promising treatment for improving the vaginal health of postmenopausal women by helping repopulate the vagina with normally existing Lactobacillus species and reconstituting the normal flora to premenopausal status. Expand
Vaginal Estrogen for Genitourinary Syndrome of Menopause: A Systematic Review
TLDR
All commercially available vaginal estrogens effectively relieve common vulvovaginal atrophy-related complaints and have additional utility in patients with urinary urgency, frequency or nocturia, SUI and UUI, and recurrent UTIs. Expand
Ultra-low-dose estriol and lactobacilli in the local treatment of postmenopausal vaginal atrophy
TLDR
The ultra-low-dose, vaginal 0.03 mg estriol–lactobacilli combination (Gynoflor®) was superior to placebo with respect to changes in VMI after the 12-day initial therapy, and the maintenance therapy of two tablets weekly was sufficient to prevent the relapse of vaginal atrophy. Expand
Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society
  • D. Portman, M. Gass
  • Medicine
  • Climacteric : the journal of the International Menopause Society
  • 2014
TLDR
GSM is defined as a collection of symptoms and signs associated with a decrease in estrogen and other sex steroids involving changes to the labia majora/minora, clitoris, vestibule/introitus, vagina, urethra and bladder. Expand
...
1
2
3
4
...